Journal of Pharmacy and Pharmaceutical Sciences

Papers
(The H4-Index of Journal of Pharmacy and Pharmaceutical Sciences is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials102
The need to redefine diabetic cardiomyopathy as a unique clinical entity that requires pharmacotherapy80
Monkeypox: Virology, Pathophysiology, Clinical Characteristics, Epidemiology, Vaccines, Diagnosis, and Treatments41
Evaluating the Effects of Agomelatine on Polysomnography Parameters in Patients with Obstructive Sleep Apnea.36
Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition34
Comparing broad and narrow phenotype algorithms: differences in performance characteristics and immortal time incurred32
Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs30
Effect of Oregon grape root extracts on P-glycoprotein mediated transport in in vitro cell lines26
Effect of Concomitant Drug Use on the Onset and Exacerbation of Diabetes Mellitus in Everolimus-Treated Cancer23
Applications of Exhaled Breath Condensate Analysis for Drug Monitoring and Bioequivalence Study of Inhaled Drugs21
Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome18
Network pharmacology and molecular docking reveal the immunomodulatory mechanism of rhubarb peony decoction for the treatment of ulcerative colitis and irritable bowel syndrome18
Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy17
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System16
Expanding the eligibility criteria for drugs in Canada’s time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines16
From fasting to fat reshaping: exploring the molecular pathways of intermittent fasting-induced adipose tissue remodeling16
0.22259283065796